FORADIL CERTIHALER
Clinical safety rating
cautionComprehensive clinical and safety monograph for FORADIL CERTIHALER (FORADIL CERTIHALER).
Formoterol is a long-acting beta2-adrenergic receptor agonist that stimulates intracellular adenyl cyclase, increasing cyclic AMP production and causing bronchodilation.
| Metabolism | Formoterol is extensively metabolized by direct glucuronidation via UGT1A1, UGT1A3, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT2B7, and UGT2B15, and O-demethylation via CYP2D6 and CYP2C19. |
| Excretion | After oral inhalation, the majority of a dose is excreted in feces (up to 70%) as unchanged drug and metabolites via biliary elimination. Renal excretion accounts for approximately 13-25% of the dose, primarily as metabolites. Unabsorbed drug accounts for the remainder. |
| Half-life | The terminal elimination half-life of formoterol (active component) ranges from 5 to 10 hours following inhalation. This supports twice-daily dosing, though clinical effect may persist longer due to prolonged receptor binding. |
| Protein binding | Formoterol is approximately 60-70% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | The volume of distribution (Vd) of formoterol is approximately 3.4 L/kg, indicating extensive distribution into tissues beyond plasma. |
| Bioavailability | Inhaled bioavailability is highly variable, approximately 20-30% of the inhaled dose reaches the lungs. Oral bioavailability is low (<10%) due to first-pass metabolism. The swallowed portion contributes minimally to systemic levels. |
| Onset of Action | Bronchodilation begins within 1-3 minutes after inhalation, with significant improvement in FEV1 observed within 5-10 minutes. Peak effect occurs at 1-3 hours. |
| Duration of Action | Bronchodilator effect lasts up to 12 hours, supporting twice-daily administration. However, duration may be shorter in some patients; regular dosing (not rescue) is recommended. |
| Molecular Weight | 383.5 |
One inhalation (12 mcg) twice daily via oral inhalation.
| Dosage form | POWDER |
| Renal impairment | No dosage adjustment required for renal impairment. Use with caution in severe impairment. |
| Liver impairment | No dosage adjustment recommended; pharmacokinetics unaffected by mild to moderate hepatic impairment. |
| Pediatric use | For children 5 years and older: one inhalation (12 mcg) twice daily. Safety and efficacy in children under 5 not established. |
| Geriatric use | No specific dose adjustment; monitor for adverse effects due to potential age-related comorbidities. |
| 1st trimester | Limited human data; animal studies show no risk. Use only if clearly needed. |
| 2nd trimester | No known risk; bronchodilator use may be continued if benefits outweigh risks. |
| 3rd trimester | May cause uterine relaxation or delay labor; use with caution near term. |
Clinical note
Comprehensive clinical and safety monograph for FORADIL CERTIHALER (FORADIL CERTIHALER).
| Placental transfer | Expected to cross placenta; molecular weight (383.5 Da) and lipophilicity suggest transfer. |
| Breastfeeding | Excretion into human milk is unknown; consider potential for infant exposure and developmental benefits of breastfeeding. |
| Lactation Rating | L3 - Limited Data |
| Teratogenic Risk | Formoterol fumarate (FORADIL CERTIHALER) is classified as FDA Pregnancy Category C. In animal studies, formoterol caused fetal malformations (e.g., omphalocele, skeletal abnormalities) at high systemic exposures. There are no adequate well-controlled studies in pregnant women. Risk to fetus cannot be ruled out; use only if potential benefit justifies potential risk. First trimester: limited data, theoretical risk based on animal findings. Second and third trimesters: may cause uterine relaxation and delay labor; avoid use near term unless clearly needed. |
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, and serum potassium levels due to potential hypokalemia. Assess fetal heart rate and uterine activity if used near term. Monitor for signs of maternal tachycardia or arrhythmia. Assess asthma control with peak expiratory flow (PEF) and symptom diaries. |
| Fertility Effects | No human studies on fertility effects. In animal studies, formoterol did not impair fertility at systemic exposures up to 15 times the maximum recommended human daily inhalation dose. Theoretical potential for beta-2 agonist to affect uterine contractility or ovulation, but clinical significance unknown. |
■ FDA Black Box Warning
Long-acting beta2-adrenergic agonists increase the risk of asthma-related death; Foradil should only be used as add-on therapy for patients not adequately controlled on other asthma controllers or whose disease severity warrants initiation of a LABA.
| Serious Effects |
Hypersensitivity to formoterol or any componentStatus asthmaticusAcute episodes of asthma requiring intensive care
| Precautions | Asthma-related death, Deterioration of disease, Use of anti-inflammatory agents, Paradoxical bronchospasm, Cardiovascular effects, Hypokalemia, Hyperglycemia, Immediate hypersensitivity reactions |
| Food/Dietary | No known food interactions. Formoterol may increase blood glucose, so monitor if diabetic. Avoid high-fat meals if using with certain devices? Not applicable. |
| Clinical Pearls | Formoterol is a long-acting beta-agonist (LABA) with rapid onset (within 5 minutes). Must not be used as monotherapy for asthma without concomitant inhaled corticosteroid. Do not use for acute bronchospasm; short-acting beta-agonists are preferred. Rinse mouth after inhalation to prevent thrush and hoarseness. Monitor for paradoxical bronchospasm, tachyphylaxis, and cardiovascular effects. Can be used once or twice daily depending on formulation. |
| Patient Advice | Do not use Foradil Certihaler to relieve sudden breathing problems; always have a rescue inhaler (e.g., albuterol) available. · Use exactly as prescribed; do not skip doses or use more than prescribed. · Rinse your mouth with water after each use to prevent mouth infection and hoarseness. · Tell your doctor if you have heart problems, high blood pressure, seizures, or thyroid disease. · If asthma, always use this medication with an inhaled corticosteroid; never use LABA alone. · Seek medical help if your symptoms worsen or rescue inhaler does not work well. · Store at room temperature away from moisture and heat. Keep cap on when not in use. |
Loading safety data…